Table 4.
Reported symptoms following immunization by method of survey completion (participant or study site staff member) and gender.
| Method, vaccine type, and gender | Participant-completed surveys (n=4549)a, n (%) | Study site-completed surveys (n=123)b, n (%) | P value | ||
| Overall AEFIc rate |
|
|
|
||
|
|
23vPPV recipients | 779 (34.09) | 26 (47.27) | .04 | |
|
|
Saline recipients | 232 (10.25) | 8 (11.76) | .69 | |
| AEFI rate by gender |
|
|
|
||
|
|
Female |
|
|
|
|
|
|
|
23vPPV recipients | 424 (37.89) | 9 (47.37) | .40 |
|
|
|
Saline recipients | 136 (12.3) | 5 (15.6) | .57 |
|
|
Male |
|
|
|
|
|
|
|
23vPPV recipients | 355 (30.45) | 17 (47.22) | .03 |
|
|
|
Saline recipients | 96 (8.3) | 3 (8.3) | .99 |
aDenominators: F=2323, M=2226. Vaccine recipients by gender. 23V PPV: M=1166, F=1119. Saline: F=1107, M=1157.
bDenominators: F=51, M=72. Vaccine doses by gender. 23V PPV: M=36, F=19. Saline: F=32, M=36.
cAEFI: adverse events following immunization.